Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.
Is lysergide finally going mainstream? Definium Therapeutics bets on DT120 ODT clinical momentum
Can DT120 ODT transform mental health treatment? Explore Definium Therapeutics’ pivotal trials and what they mean for psychedelic psychiatry.